OpenAI introduced MedChemBench on November 20, a benchmark containing 99 medicinal chemistry problems testing molecular reconstruction, evidence interpretation, compound selection, and property prediction. GPT-6.2 Astra achieved 84.5% of available credit at high reasoning effort, compared with 83.3% for GPT-6 Astra. The benchmark draws on 117 papers and patents. OpenAI cautioned that the results do not establish drug discovery ability or support better laboratory decisions, noting that prior exposure to source material cannot be ruled out and each response was a single attempt without tools, feedback, or new experiments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice or encourage the buying or selling of crypto assets. It is intended to provide information about industry developments and is not directly related to the services offered by Gate TR. Although information obtained from third-party sources has been carefully reviewed, Gate TR assumes no responsibility for any errors or omissions. Crypto assets involve high risks and may experience significant price fluctuations. Before making any investment decisions, you should assess your financial situation and risk tolerance, conduct your own research, and make decisions independently.